# Development of Visual Function Evaluation Method

> **NCT03281005** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 18 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03281005
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281005, "Development of Visual Function Evaluation Method". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03281005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*